<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36569946</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>27</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>19</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Immunogenicity and safety of an inactivated enterovirus 71 vaccine coadministered with trivalent split-virion inactivated influenza vaccine: A phase 4, multicenter, randomized, controlled trial in China.</ArticleTitle><Pagination><StartPage>1080408</StartPage><MedlinePgn>1080408</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1080408</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2022.1080408</ELocationID><Abstract><AbstractText Label="BACKGROUND">Few data exist on the immunogenicity and safety of an inactivated enterovirus 71 vaccine (EV71 vaccine) coadministered with trivalent split-virion inactivated influenza vaccine (IIV3) in infants.</AbstractText><AbstractText Label="METHODS">This trial was a phase 4, randomized, controlled trial. Infants aged 6-11 months were eligible, with no history of hand, foot and mouth disease (HFMD) and no history of EV71 vaccine or any influenza vaccine. Eligible infants were randomly assigned to EV71+IIV3 group, EV71 group or IIV3 group. Blood samples were collected on day 0 and 56.</AbstractText><AbstractText Label="RESULTS">Between September 2019 and June 2020, 1151 infants met eligibility criteria and 1134 infants were enrolled. 1045 infants were included in the per-protocol population, including 347 in the EV71+IIV3 group, 343 in the EV71 group, and 355 in the IIV3 group. The seroconversion rate (98.56% vs 98.54%; seroconversion rates difference of 0.02% [95% CI: 0.70-0.98]) and GMT (419.05 vs 503.72; GMT ratio of 0.83 [95% CI 0.70 - 0.98]) of EV71 neutralizing antibodies in the EV71+IIV3 group was not inferior to those in the EV71 group. The non-inferiority results for influenza virus antibodies (A/H1N1, A/H3N2 and B) showed that the seroconversion rates and GMTs of the EV71+IIV3 group were non-inferiority to those of the IIV3 group. Systemic and local adverse event rates were similar between groups. None of serious adverse events (SAEs) were related to vaccination.</AbstractText><AbstractText Label="CONCLUSIONS">Coadministration of the EV71 vaccine with IIV3 was safe and did not interfere with immunogenicity. These findings support a viable immunization strategy for infants with the EV71 vaccine coadministered with IIV3 in China. This trial is registered with ClinicalTrials.gov, number NCT04091880.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Chen, Xiao, Ye, Jiang, He, Luo, Chen, Shi, Mu, Chen, Guo, Zhang, Li, Guan, Chen and Yang.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yaping</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Immunization Programme Department, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Yanhui</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Medical Affairs Department, China National Biotec Group Company Limited, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute for Communicable Disease Control and Prevention, Henan Provincial Center for Disease Control and Prevention, Zhengzhou, Henan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Feng</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute of Expanded Programme on Immunization, Guizhou Provincial Center for Disease Control and Prevention, Guiyang, Guizhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Hanqing</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Immunization Programme Department, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Linyun</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Medical Affairs Department, China National Biotec Group Company Limited, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Haiping</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Medical Affairs Department, China National Biotec Group Company Limited, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Lubin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Expanded Programme on Immunization, Henan Provincial Center for Disease Control and Prevention, Zhengzhou, Henan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mu</LastName><ForeName>Qiuyue</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Institute of Expanded Programme on Immunization, Guizhou Provincial Center for Disease Control and Prevention, Guiyang, Guizhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Medical Affairs Department, Wuhan Institute of Biological Products Company Limited, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Xue</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Medical Affairs Department, Changchun Institute of Biological Products Company Limited, Changchun, Jilin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medical Affairs Department, China National Biotec Group Company Limited, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Expanded Programme on Immunization, Henan Provincial Center for Disease Control and Prevention, Zhengzhou, Henan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guan</LastName><ForeName>Qinghu</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Institute of Expanded Programme on Immunization, Guizhou Provincial Center for Disease Control and Prevention, Guiyang, Guizhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Zhiping</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Immunization Programme Department, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Xiaoming</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Medical Affairs Department, China National Biotec Group Company Limited, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research and Development Department, National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Company Limited, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04091880</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D017429">Clinical Trial, Phase IV</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="Y">Influenza Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="Y">Influenza A Virus, H1N1 Subtype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053122" MajorTopicYN="N">Influenza A Virus, H3N2 Subtype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006385" MajorTopicYN="N">Hemagglutination Inhibition Tests</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="Y">Influenza, Human</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014771" MajorTopicYN="N">Virion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006679" MajorTopicYN="Y">HIV Seropositivity</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">coadministration</Keyword><Keyword MajorTopicYN="N">immunogenicity</Keyword><Keyword MajorTopicYN="N">inactivated enterovirus 71 vaccine</Keyword><Keyword MajorTopicYN="N">safety</Keyword><Keyword MajorTopicYN="N">trivalent split-virion inactivated influenza vaccine</Keyword></KeywordList><CoiStatement>XY, YX, LL, HC, and MZ are employees of the China National Biotec Group. WC is the employee of the Wuhan Institute of Biological Products. XG is the employee of the Changchun Institute of Biological Products. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>26</Day><Hour>4</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36569946</ArticleId><ArticleId IdType="pmc">PMC9772018</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.1080408</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nasri D, Bouslama L, Pillet S, Bourlet T, Aouni M, Pozzetto B. Basic rationale, current methods and future directions for molecular typing of human enterovirus. Expert Rev Mol diagnostics (2007) 7(4):419&#x2013;34. doi:&#xa0;10.1586/14737159.7.4.419</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14737159.7.4.419</ArticleId><ArticleId IdType="pubmed">17620049</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito S, Principi N. Hand, foot and mouth disease: Current knowledge on clinical manifestations, epidemiology, aetiology and prevention. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol (2018) 37(3):391&#x2013;8. doi:&#xa0;10.1007/s10096-018-3206-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-018-3206-x</ArticleId><ArticleId IdType="pubmed">29411190</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis (2010) 10(11):778&#x2013;90. doi:&#xa0;10.1016/s1473-3099(10)70194-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P, Huang Y, Zhu D, Yang S, Hu D. Risk factors for severe hand-Foot-Mouth disease in China: A systematic review and meta-analysis. Front Pediatr (2021) 9:716039. doi:&#xa0;10.3389/fped.2021.716039</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2021.716039</ArticleId><ArticleId IdType="pmc">PMC8631475</ArticleId><ArticleId IdType="pubmed">34858899</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing W, Liao Q, Viboud C, Zhang J, Sun J, Wu JT, et al. . Hand, foot, and mouth disease in China, 2008-12: An epidemiological study. Lancet Infect Dis (2014) 14(4):308&#x2013;18. doi:&#xa0;10.1016/s1473-3099(13)70342-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1473-3099(13)70342-6</ArticleId><ArticleId IdType="pmc">PMC4035015</ArticleId><ArticleId IdType="pubmed">24485991</ArticleId></ArticleIdList></Reference><Reference><Citation>Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, et al. . Estimates of global seasonal influenza-associated respiratory mortality: A modelling study. Lancet (London England) (2018) 391(10127):1285&#x2013;300. doi:&#xa0;10.1016/s0140-6736(17)33293-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(17)33293-2</ArticleId><ArticleId IdType="pmc">PMC5935243</ArticleId><ArticleId IdType="pubmed">29248255</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Li Y, O'Brien KL, Madhi SA, Widdowson MA, Byass P, et al. . Global burden of respiratory infections associated with seasonal influenza in children under 5 years in 2018: A systematic review and modelling study. Lancet Global Health (2020) 8(4):e497&#x2013;510. doi:&#xa0;10.1016/s2214-109x(19)30545-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2214-109x(19)30545-5</ArticleId><ArticleId IdType="pmc">PMC7083228</ArticleId><ArticleId IdType="pubmed">32087815</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu H, Huang J, Huai Y, Guan X, Klena J, Liu S, et al. . The substantial hospitalization burden of influenza in central China: Surveillance for severe, acute respiratory infection, and influenza viruses, 2010-2012. Influenza other Respir viruses (2014) 8(1):53&#x2013;65. doi:&#xa0;10.1111/irv.12205</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.12205</ArticleId><ArticleId IdType="pmc">PMC4177798</ArticleId><ArticleId IdType="pubmed">24209711</ArticleId></ArticleIdList></Reference><Reference><Citation>Geng Y, Zhang L. Impact of non-pharmaceutical interventions during covid-19 pandemic on pertussis, scarlet fever and hand-Foot-Mouth disease in China. J infection (2022) 84(2):e13&#x2013;e5. doi:&#xa0;10.1016/j.jinf.2021.12.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2021.12.023</ArticleId><ArticleId IdType="pmc">PMC8694816</ArticleId><ArticleId IdType="pubmed">34953908</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng L, Zhang T, Wang Q, Xie Y, Peng Z, Zheng J, et al. . Impact of covid-19 outbreaks and interventions on influenza in China and the united states. Nat Commun (2021) 12(1):3249. doi:&#xa0;10.1038/s41467-021-23440-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-23440-1</ArticleId><ArticleId IdType="pmc">PMC8167168</ArticleId><ArticleId IdType="pubmed">34059675</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang W, Li X, Tan M, Cheng Y, Chen T, Wei H, et al. . Epidemiological and virological surveillance of seasonal influenza viruses - China, 2020-2021. China CDC weekly (2021) 3(44):918&#x2013;22. doi:&#xa0;10.46234/ccdcw2021.224</Citation><ArticleIdList><ArticleId IdType="doi">10.46234/ccdcw2021.224</ArticleId><ArticleId IdType="pmc">PMC8563335</ArticleId><ArticleId IdType="pubmed">34745692</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalligeros M, Shehadeh F, Mylona EK, Dapaah-Afriyie C, van Aalst R, Chit A, et al. . Influenza vaccine effectiveness against influenza-associated hospitalization in children: A systematic review and meta-analysis. Vaccine (2020) 38(14):2893&#x2013;903. doi:&#xa0;10.1016/j.vaccine.2020.02.049</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2020.02.049</ArticleId><ArticleId IdType="pubmed">32113808</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Zhou Y, Cheng Y, Wu P, Zhou C, Cui P, et al. . Effectiveness of ev-A71 vaccination in prevention of paediatric hand, foot, and mouth disease associated with ev-A71 virus infection requiring hospitalisation in henan, China, 2017-18: A test-negative case-control study. Lancet Child Adolesc Health (2019) 3(10):697&#x2013;704. doi:&#xa0;10.1016/s2352-4642(19)30185-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2352-4642(19)30185-3</ArticleId><ArticleId IdType="pmc">PMC8713082</ArticleId><ArticleId IdType="pubmed">31375313</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinleyici EC, Borrow R, Safadi MAP, van Damme P, Munoz FM. Vaccines and routine immunization strategies during the covid-19 pandemic. Hum Vaccines immunotherapeutics (2021) 17(2):400&#x2013;7. doi:&#xa0;10.1080/21645515.2020.1804776</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2020.1804776</ArticleId><ArticleId IdType="pmc">PMC7899627</ArticleId><ArticleId IdType="pubmed">32845739</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, Liang ZL, Li XL, Ge HM, Meng FY, Mao QY, et al. . Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: A randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet (London England) (2013) 381(9871):1037&#x2013;45. doi:&#xa0;10.1016/s0140-6736(12)61764-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(12)61764-4</ArticleId><ArticleId IdType="pubmed">23352749</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X, et al. . Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. New Engl J Med (2014) 370(9):818&#x2013;28. doi:&#xa0;10.1056/NEJMoa1304923</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1304923</ArticleId><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei M, Meng F, Wang S, Li J, Zhang Y, Mao Q, et al. . 2-year efficacy, immunogenicity, and safety of vigoo enterovirus 71 vaccine in healthy Chinese children: A randomized open-label study. J Infect Dis (2017) 215(1):56&#x2013;63. doi:&#xa0;10.1093/infdis/jiw502</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiw502</ArticleId><ArticleId IdType="pubmed">28077584</ArticleId></ArticleIdList></Reference><Reference><Citation>Head JR, Collender PA, Lewnard JA, Skaff NK, Li L, Cheng Q, et al. . Early evidence of inactivated enterovirus 71 vaccine impact against hand, foot, and mouth disease in a major center of ongoing transmission in China, 2011-2018: A longitudinal surveillance study. Clin Infect Dis an Off Publ Infect Dis Soc America (2020) 71(12):3088&#x2013;95. doi:&#xa0;10.1093/cid/ciz1188</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciz1188</ArticleId><ArticleId IdType="pmc">PMC7819528</ArticleId><ArticleId IdType="pubmed">31879754</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Chang S, Wang R, Xiao Y, Li F, Xu Q, et al. . Immunogenicity and safety of an inactivated enterovirus 71 vaccine administered simultaneously with hepatitis b virus vaccine, group a meningococcal polysaccharide vaccine, measles-rubella combined vaccine and Japanese encephalitis vaccine: A multi-center, randomized, controlled clinical trial in China. Vaccines (2022) 10(6):895. doi:&#xa0;10.3390/vaccines10060895</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10060895</ArticleId><ArticleId IdType="pmc">PMC9230521</ArticleId><ArticleId IdType="pubmed">35746502</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Yang W, Zhang C, Wu H, Wang R, Ding Q, et al. . Immunogenicity and safety of an inactivated enterovirus 71 vaccine Co-administered with measles-Mumps-Rubella vaccine and live-attenuated Japanese encephalitis vaccine: A phase 4, single-center, randomized controlled trial. Hum Vaccines immunotherapeutics (2021) 17(12):5348&#x2013;54. doi:&#xa0;10.1080/21645515.2021.2010428</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2021.2010428</ArticleId><ArticleId IdType="pmc">PMC8903949</ArticleId><ArticleId IdType="pubmed">34905446</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Liang Z, Zeng J, Zhang J, He P, Su J, et al. . Immunogenicity and safety of an inactivated enterovirus 71 vaccine administered simultaneously with hepatitis b vaccine and group a meningococcal polysaccharide vaccine: A phase 4, open-label, single-center, randomized, noninferiority trial. J Infect Dis (2019) 220(3):392&#x2013;9. doi:&#xa0;10.1093/infdis/jiz129</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiz129</ArticleId><ArticleId IdType="pubmed">30891604</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z, Liao Y, Li Y, Jiang G, Huang Z, Yang H, et al. . Immunogenicity and safety of the inactivated enterovirus 71 vaccine administered concomitantly with the measles-rubella vaccine in infants aged 8 months in China: A noninferiority randomized controlled trial. Vaccine (2022) 40(33):4709&#x2013;15. doi:&#xa0;10.1016/j.vaccine.2022.06.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.06.027</ArticleId><ArticleId IdType="pubmed">35753838</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>